What is Elle, MD?
Based in Nova Scotia, Canada, Elle, MD is a female-founded biotechnology enterprise focused on the development of The Better Ring. This innovative, non-hormonal contraceptive device represents a significant shift in the reproductive health landscape, aiming to provide a dual-indication solution that includes emergency contraception. By prioritizing user agency and physiological well-being, the company is carving out a distinct niche in the health-tech market, addressing long-standing gaps in contraceptive efficacy and safety profiles. The firm's commitment to non-hormonal alternatives positions it as a disruptive force in a market traditionally dominated by systemic hormonal interventions.
How much funding has Elle, MD raised?
Elle, MD has raised a total of $784K across 1 funding round:
Angel/Pre-Seed
$784K
Angel/Pre-Seed (2026): $784K with participation from Invest Nova Scotia, Spring, Startup TNT, Queen's University, New Brunswick Innovation Foundation, and CBDC Nortip
Key Investors in Elle, MD
Invest Nova Scotia
A provincial agency dedicated to fostering economic growth by providing capital, incubation, and acceleration services to high-potential startups.
Spring
A global incubator and B Corporation that empowers impact-driven entrepreneurs through specialized accelerator programs and angel investor training.
Startup TNT
A community-focused investment organization that facilitates capital access for Canadian startups through biannual summits and collaborative angel networks.
What's next for Elle, MD?
Following this major enterprise-level funding, Elle, MD is expected to prioritize the regulatory pathway and manufacturing scale-up for The Better Ring. The strategic allocation of capital will likely focus on clinical trials and the necessary infrastructure to support a dual-indication product launch. As the company moves through its current lifecycle stage, the focus will shift toward establishing robust distribution channels and securing intellectual property protections that solidify its competitive advantage. Investors remain optimistic that the firm's unique value proposition will attract further institutional interest as it approaches commercialization, potentially setting a new standard for women's health technology on a global scale.
See full Elle, MD company page
